A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies
The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Background The primary systemic vasculitides usually associated with autoantibodies to neutrophil cytoplasmic antigens include Wegener's granulomatosis and microscopic polyangiitis. We investigated whether exposure to cyclophosphamide in patients with generalized vasculitis could be reduced by substitution of azathioprine at remission. Methods We studied patients with a new diagnosis of generalized vasculitis and a serum creatinine concentration of 5.7 mg per deciliter (500 micromol per liter) or less. All patients received at least three months of therapy with oral cyclophosphamide and prednisolone. After remission, patients were randomly assigned to continued cyclophosphamide therapy (1.5 mg per kilogram of body weight per day) or a substitute regimen of azathioprine (2 mg per kilogram per day). Both groups continued to receive prednisolone and were followed for 18 months from study entry. Relapse was the primary end point. Results Of 155 patients studied, 144 (93 percent) entered remission and were randomly assigned to azathioprine (71 patients) or continued cyclophosphamide (73 patients). There were eight deaths (5 percent), seven of them during the first three months. Eleven relapses occurred in the azathioprine group (15.5 percent), and 10 occurred in the cyclophosphamide group (13.7 percent, P=0.65). Severe adverse events occurred in 15 patients during the induction phase (10 percent), in 8 patients in the azathioprine group during the remission phase (11 percent), and…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment includes prednisone, cyclophosphamide, or methotrexate.237,238,245”
From International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (2018) · cites this paper as [245]
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Self-citationWegener Granulomatosis: An Analysis of 158 Patients
Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., & Fauci, A. S. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-6-488 · Cited by 2,857
FAUCI, A. S., HAYNES, B. F., KATZ, P., & WOLFF, S. M. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-1-76 · Cited by 2,001
Short form 36 (SF36) health survey questionnaire: normative data for adults of working age.
Jenkinson, C., Coulter, A., & Wright, L. (1993) · BMJ · doi:10.1136/bmj.306.6890.1437 · Cited by 1,718
Falk, R. J., Terrell, R. S., Charles, L. A., & Jennette, J. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4115 · Cited by 1,261
Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.
Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056
Self-citationSavige, J., Gillis, D., Benson, E., Davies, D., Esnault, V., Falk, R. J., Chris Hagen, E., Jayne, D., Charles Jennette, J., Paspaliaris, B., et al. (1999) · American Journal of Clinical Pathology · doi:10.1093/ajcp/111.4.507 · Cited by 884
Self-citationValidation of rheumatoid arthritis improvement criteria that include simplified joint counts
van Gestel, A. M., Haagsma, C. J., & van Riel, P. L. C. M. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199810)41:10<1845::aid-art17>3.0.co;2-k · Cited by 803
Research works printed but not linked: 10
- Jennette JC, 1989, Am J Pathol, 135, 921
- Hauer HA, 1998, Clin Exp Immunol, 112, 28
- 10.1002/(SICI)1096-9896(200002)190:3<349::AID-PATH524>3.0.CO;2-A · doi:10.1002/(sici)1096-9896(200002)190:3<349::aid-path524>3.0.co;2-a
- 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J · DOI · Paper page
- Jayne DR, 1995, QJM, 88, 127
- Luqmani RA, 1994, QJM, 87, 671
- Bacon PA, 1995, Clin Exp Rheumatol, 13, 275
- 10.1002/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q · doi:10.1002/1529-0131(199810)41:10<1835::aid-art16>3.0.co;2-q
- Szpirt WM, 1996, Int J Artif Organs, 19, 501
- 10.1002/1529-0131(200105)44:5<1149::AID-ANR197>3.0.CO;2-F · DOI · Paper page
Cited by
Items 801–900 of 999
Vasculitides Throughout History and Their Clinical Treatment Today
Gamarra, A. I., Peñaranda-Parada, E. A., & Espinoza, L. R. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0210-x · Cited by 6
“[104] from EUVAS (the European Vasculitis Study Group) published in the New England Journal of Medicine a randomized study on 155 patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis in which the use of azathioprine was compared with daily doses of cyclophosphamide in the maintenance of remis…”
BackgroundMethodRecent advances in understanding and treating vasculitis
Koster, M. J., & Warrington, K. J. (2016) · F1000Research · doi:10.12688/f1000research.8403.1 · Cited by 5
POLYARTERITIS NODOSA AND CUTANEOUS POLYARTERITIS NODOSA
Dillon, M. J., & Özen, S. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-6581-4.10032-9 · Cited by 5
Weyand, C. M., & Goronzy, J. J. (2008) · Springer eBooks · doi:10.1007/978-0-387-68566-3_21 · Cited by 5
Quinn, K. A., Monti, S. M., Christensen, R., Jayne, D. R. W., Langford, C. A., Lanier, G. E., Mahr, A., Pagnoux, C., Shea, B., Viðarsdóttir, M. B., et al. (2022) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2022.152021 · Cited by 6
Self-citationLearoyd, A., Arnold, L., Reid, F., Beckley‐Hoelscher, N., Casian, A., Sangle, S. R., Morton, N., Nel, L., Cape, A., John, S., et al. (2023) · Trials · doi:10.1186/s13063-023-07108-3 · Cited by 5
“Considerations Loss to follow-up is not expected as trials in a similar cohort only had a < 5% drop-out rate [21, 32, 33].”
BackgroundMethodSelf-citationAnti-cytokine targeted therapies for ANCA-associated vasculitis
Bała, M. M., Malecka-Massalska, T. J., Koperny, M., Zając, J., & Szczeklik, W. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008333 · Cited by 5
“Jayne 2003 Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JWC, Dadoniene J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.”
BackgroundMa, T., Liu, Y., Chen, M., & Zhao, M. (2018) · Clinical Rheumatology · doi:10.1007/s10067-018-4100-8 · Cited by 5
Immunotherapy in Renal Diseases
Kher, A., & Kher, V. (2012) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.04.007 · Cited by 5
Treatment of Wegener’s granulomatosis
Riccieri, V., & Valesini, G. (2011) · Reumatismo · doi:10.4081/reumatismo.2004.69 · Cited by 5
How to recognise and treat peripheral nervous system vasculitis
Marsh, E. A., Davies, L., & Llewelyn, J. (2013) · Practical Neurology · doi:10.1136/practneurol-2012-000464 · Cited by 5
Akioka, Y., Hattori, M., Kawaguchi, H., & Ito, K. (2004) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1526-0968.2004.00150.x · Cited by 5
ANCA Testing in Monitoring the Activity of the Disease
Tervaert, J. W. C. (2003) · Kidney & Blood Pressure Research · doi:10.1159/000072989 · Cited by 5
Self-citationNotes on the kidney and its diseases for the neurologist
Zandi, M. S., & Coles, A. J. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.091991 · Cited by 5
ANCA-associated vasculitis: pathogenesis, novel markers of the disease and emerging therapies.
Dhaygude, A. P., Erdbrüegger, U., Haubitz, M., & Woywodt, A. (2009) · PubMed · Cited by 5
Polyarteritis nodosa and microscopic polyangiitis
Watts, R. A., & Scott, D. G. I. (2011) · Elsevier eBooks · doi:10.1016/b978-0-323-06551-1.00151-2 · Cited by 5
Entwicklung von Morbidität und Mortalität bei ANCA-assoziierten Vaskulitiden
Reinhold‐Keller, E., & Moosig, F. (2011) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-011-0756-z · Cited by 5
García, F. J. V., Parra, M., Medina, L. F., & Estrada, J. (2005) · Cited by 5
Implications of antineutrophil cytoplasmic antibody status when switching to maintenance therapy
Hoffman, G. S., Stone, J. H., & Langford, C. A. (2005) · Arthritis Care & Research · doi:10.1002/art.20921 · Cited by 5
Langford, C. A., & Hoffman, G. S. (2012) · Arthritis & Rheumatism · doi:10.1002/art.37791 · Cited by 5
Watts, R. A., Lane, S. E., & Scott, D. G. I. (2003) · doi:10.1002/9781444315844.ch13 · Cited by 5
The treatment of lupus nephritis
D’Cruz, D. P., & Hughes, G. R. V. (2005) · BMJ · doi:10.1136/bmj.330.7488.377 · Cited by 5
Persistent Hematuria in ANCA Vasculitis
Mahoney, S., & Nachman, P. H. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14101217 · Cited by 5
Ghafari-Saravi, A., Haussmann, A., Wu, J., & Cheng, K. (2024) · JAAD Case Reports · doi:10.1016/j.jdcr.2024.03.005 · Cited by 4
Samad, A., Wobma, H., & Casey, A. M. H. (2024) · Pediatric Pulmonology · doi:10.1002/ppul.27068 · Cited by 7
Reclassification and the introduction of biologicals
Kallenberg, C. G. M. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.284 · Cited by 4
New therapeutic approaches for ANCA-associated vasculitides
Chaigne, B., & Guillevin, L. (2016) · La Presse Médicale · doi:10.1016/j.lpm.2016.05.003 · Cited by 4
Rapidly Progressive Glomerulonephritis
Bagga, A., & Menon, S. (2016) · Springer eBooks · doi:10.1007/978-3-662-52972-0_22 · Cited by 4
Chen, L., Ni, A., Huang, X., Ren, P., Lan, L., Wang, Y., Zhu, Y., Xu, Y., Chen, J., & Han, F. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/6a6b6j · Cited by 4
Adult and childhood vasculitis
Younger, D. S. (2023) · Handbook of clinical neurology · doi:10.1016/b978-0-323-98818-6.00008-x · Cited by 5
Elahi, T., Ahmed, S., Mubarak, M., & Ahmed, E. (2024) · Clinical Rheumatology · doi:10.1007/s10067-024-07047-7 · Cited by 4
“Progression to end-stage kidney disease (ESKD) can be prevented by prompt diagnosis and timely initiation of immunosuppressive therapy established by randomized controlled trials (RCTs) [7, 8]; hence, the 5-year survival is increased up to about 75% [9].”
Kim, H., Chun, S., Sun, S., Cho, H., Kim, T., Lee, Y., Chie, E. K., Yang, K., & Kim, M. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.807 · Cited by 5
“Low-dose Cy suppressed the radiation-induced upregulation of HIF-1α in the tumors. studies for rheumatic diseases [12,13].”
Targeting the complement system in ANCA-associated vasculitis management
de Groot, K. (2025) · Rheumatology · doi:10.1093/rheumatology/keaf539 · Cited by 5
Tesař, V., & Hrušková, Z. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1059822 · Cited by 4
“After the already mentioned CYCAZAREM trial had demonstrated that early switch to azathioprine was similarly effective as continued treatment with cyclophosphamide [22], azathioprine became a treatment of choice for maintenance treatment in AAV.”
BackgroundResultUhm, W.-S. (2010) · Journal of Rheumatic Diseases · doi:10.4078/jkra.2010.17.2.108 · Cited by 4
Vandergheynst, F. A. (2013) · Acta Clinica Belgica · doi:10.2143/acb.3436 · Cited by 4
GLOMERULONEPHRITIS AND THE NEPHROTIC SYNDROME IN PREGNANCY
Hall, M., & Brunskill, N. J. (2010) · Fetal and Maternal Medicine Review · doi:10.1017/s0965539510000045 · Cited by 4
Various Forms of Life in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Hoffman, G. S., & Langford, C. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-5-200603070-00020 · Cited by 4
“The editorial compares the treatment results of our studies with 2 treatment trials (11, 12), but, as the authors point out, comparing the results of different trials is “risky” and may introduce bias.”
BackgroundResultTuberculosis versus vasculitis.
Baig, Z. F., Raja, K. M., & Abbas, F. (2014) · PubMed · Cited by 4
Beketova, T. V., Volkov, M., & Насонов, Е. Л. (2016) · Terapevticheskii arkhiv · doi:10.17116/terarkh201688586-92 · Cited by 4
Vasculitis and Other Arteriopathies
Warrington, K. J., & Cooper, L. T. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5223-4.00076-7 · Cited by 4
Acute glomerulonephritis and rapidly progressive glomerulonephritis
Vehaskari, V. M., & Avilés, D. (2006) · CRC Press eBooks · doi:10.3109/9780203482308-14 · Cited by 4
Remission maintenance in ANCA-associated vasculitis: does one size fit all?
Berti, A., & Specks, U. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1693260 · Cited by 4
“Consequently, recognized major outcomes of clinical trials in AAV include risk of any relapse, risk of severe relapse and time to relapse during follow-up [8,9].”
BackgroundB-cell treatment in ANCA-associated vasculitis
Karras, A., Lazareth, H., & Chauvet, S. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez605 · Cited by 4
Gene variants and treatment outcomes in antineutrophil cytoplasmic antibody-associated vasculitis
Hessels, A. C., Sanders, J., Rutgers, A., & Stegeman, C. A. (2020) · The Pharmacogenomics Journal · doi:10.1038/s41397-020-0176-z · Cited by 4
Jayne, D. R. W. (2020) · doi:10.1093/med/9780198746690.003.0459 · Cited by 4
Self-citationHow best to manage relapse and remission in ANCA-associated vasculitis
Puéchal, X., & Guillevin, L. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2122954 · Cited by 6
“and relapse rates for both groups [3].”
ANCA-Associated Vasculitis: Practical Issues in Management
Roper, T., & Salama, A. D. (2023) · Indian Journal of Nephrology · doi:10.4103/ijn.ijn_346_23 · Cited by 4
“74 Later trials aimed to determine if alternative PO IS agents would be as effective as AZA at maintaining remission but with fewer AEs.”
BackgroundKanazawa Study Group for Renal Diseases and Hypertension, Kitagawa, K., Furuichi, K., Shinozaki, Y., Toyama, T., Kitajima, S., Hara, A., Iwata, Y., Sakai, N., Kaneko, S., et al. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0798-4 · Cited by 4
“mizoribine, and biological agents were reported to be effective as immunosuppressants in patients with ANCArelated vasculitis [15–18].”
BackgroundThomas, S. S., Clements, P. J., & Fürst, D. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-09138-1.00058-9 · Cited by 4
Makhzoum, J., & Pagnoux, C. (2017) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2017.04.003 · Cited by 5
EULAR guidelines on ANCA-associated vasculitis in the real life
Marvisi, C., Galli, E., Manzini, C. U., Sandri, G., & Salvarani, C. (2021) · Beyond Rheumatology · doi:10.4081/br.2020.50 · Cited by 5
Harper, L. (2009) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e328331cfeb · Cited by 4
Historia del tratamiento de las vasculitis primarias
Gamarra, A. I., Peñaranda-Parada, E. A., Santana, L. J. C., Quintana‐López, G., Restrepo-Suárez, J. F., Arbeláez-Cortés, Á., & Rondón-Herrera, F. (2012) · Revista Colombiana de Reumatología · doi:10.1016/s0121-8123(12)70022-1 · Cited by 3
Vascularites rénales associées aux ANCA
Vanhille, P., Vrigneaud, L., & Quéméneur, T. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2011.11.009 · Cited by 4
O’Brien, F., Abdalla, A., Wong, L., Traynor, C. A., Cheriyan, P., Kok, H. K., Casserly, L. F., Dorman, A. M., & Conlon, P. J. (2013) · Case Reports in Nephrology and Dialysis · doi:10.1159/000347142 · Cited by 4
Pagnoux, C. (2007) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2007.09.019 · Cited by 4
Ozaki, S. (2013) · Clinical and Experimental Nephrology · doi:10.1007/s10157-013-0821-9 · Cited by 4
Management of systemic lupus erythematosus in Chinese patients
Mok, C. C. (2007) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.3.6.925 · Cited by 4
Silva, F., & Marcela Cisternas, M. (2013) · Revista médica de Chile · doi:10.4067/s0034-98872013000600011 · Cited by 4
Almroth, G., Berlin, G., Andersson, B. A., & Hahn‐Zoric, M. (2008) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590802519354 · Cited by 4
L38. How to treat primary vasculitis of the central nervous system
Pagnoux, C., & de Boysson, H. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.01.038 · Cited by 4
The role of biologics in treatment of ANCA-associated vasculitis
Dharmapalaiah, C., & Watts, R. A. (2011) · Modern Rheumatology · doi:10.1007/s10165-011-0548-y · Cited by 8
Ziarniniakowatość z Zapaleniem Naczyń—Obraz Kliniczny i Przegląd Aktualnych Opcji Terapeutycznych
Lembicz, M., Batura‐Gabryel, H., & Nowicka, A. (2013) · Advances in respiratory medicine · doi:10.5603/piap.2014.0010 · Cited by 5
Systemic vasculitides: an overview
Jones, R. B., & Savage, C. O. S. (2014) · Medicine · doi:10.1016/j.mpmed.2013.12.009 · Cited by 4
Conditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitides
Holle, J. U., Moosig, F., Dalhoff, K., & Gross, W. L. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3307 · Cited by 5
“After successful remission induction (of 3 to 6 months), MPA and WG patients should be switched to maintenance therapy with medium-potent immunosuppression (azathio prin, MTX or lefl unomide) [ 47-49 ].”
BackgroundSelf-citationMoog, P., & Thuermel, K. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s79080 · Cited by 4
“…has become the mainstay of maintenance therapy in AAVs, mainly on the basis of the cyclophosphamide versus azathioprine for remission in generalised vasculitis (CYCAZAREM) trial, 88 which found azathioprine to be as effective as oral cyclophosphamide after induction with oral cyclophosphamide.”
Glomerular Disorders and Nephrotic Syndromes
Appel, G. B., & Radhakrishnan, J. (2012) · Goldman's Cecil Medicine · doi:10.1016/b978-1-4377-1604-7.00123-8 · Cited by 4
Jayne, D. R. W. (2004) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2004.s16 · Cited by 4
“These presentations are fatal when untreated but now around 90% achieve disease control with the combination of corticosteroids and the alkylating agent cyclophosphamide (3).”
BackgroundSelf-citationPulmonary Vasculitis and Hemorrhage
Specks, U. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0792-8.00059-3 · Cited by 4
Autoimmune and Inflammatory Disorders
Bartt, R. E., & Topel, J. L. (2007) · Elsevier eBooks · doi:10.1016/b978-141603618-0.10050-5 · Cited by 4
Ocular manifestations of Wegener’s granulomatosis
Taylor, S. R. J., Salama, A. D., Pusey, C. D., & Lightman, S. (2007) · Expert Review of Ophthalmology · doi:10.1586/17469899.2.1.91 · Cited by 4
Self-citationANCA-negative glomerulonephritis associated with nonasthmatic Churg–Strauss syndrome
Chemmalakuzhy, A. J., Zhou, X. J., & Hedayati, S. S. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph0922 · Cited by 5
End‐Stage Renal Disease and Vasculitis
de Groot, K., & Pusey, C. D. (2012) · doi:10.1002/9781118355244.ch49 · Cited by 4
Self-citationSchönermarck, U., Rau, S., & Fischereder, M. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34590 · Cited by 4
Therapie der primär systemischen Vaskulitiden
de Groot, K., Gross, W. L., & Hellmich, B. (2003) · Der Internist · doi:10.1007/s00108-003-1064-8 · Cited by 4
“Eine aktuelle,prospektive,kontrollierte, randomisierte Studie [16] prüfte, ob Azathioprin 2 mg/kgKG zur Remissionserhaltung bei 158 Patienten mit AAV im Generalisationsstadium ebenso effektiv ist wie Cyclophosphamid 1,5 mg/kgKG nach einheitlicher Remissionsinduktionstherapie mit CYC und Prednisolon.”
BackgroundSelf-citationSunderkötter, C. H., & Kolde, G. (2004) · CRC Press eBooks · doi:10.1201/b14248-33 · Cited by 4
Draibe, J. B., Marco, H., Ibernón, M., Agraz, I., Arcal, C., Freiría, X. B., Cabrera, V., Silva, I. D., Encarnación, M. M. D., Fulladosa, X., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226793 · Cited by 4
Therapeutisches Vorgehen bei ANCA-assoziierten Vaskulitiden
Hellmich, B. (2015) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-014-1532-7 · Cited by 3
Recent advances in managing systemic sclerosis
Aringer, M., & Erler, A. (2017) · F1000Research · doi:10.12688/f1000research.10022.1 · Cited by 3
Maintenance of Remission in antineutrophil cytoplasm antibody‐associated vasculitides
Guillevin, L., & Terrier, B. (2018) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13303 · Cited by 3
Microscopic polyangiitis and granulomatosis with polyangiitis
Pagnoux, C. (2019) · European Respiratory Society eBooks · doi:10.1183/2312508x.10014619 · Cited by 3
Lung involvement in ANCA-associated vasculitis
Unizony, S. H., & Abril, A. (2022) · Technical report · doi:10.1016/b978-0-323-91083-5.00007-4 · Cited by 4
Current perspectives on the diagnosis, assessment, and management of vasculitic neuropathy
Fukami, Y., Koike, H., & Katsuno, M. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2166831 · Cited by 5
Management of antineutrophil cytoplasmic antibody-associated vasculitis: a changing tide
Krishnan, A., Walsh, M. W., & Collister, D. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000877 · Cited by 3
Hara, A., Sada, K., Wada, T., Amano, K., Dobashi, H., Atsumi, T., Sugihara, T., Hirayama, K., Banno, S., Murakawa, Y., et al. (2023) · Modern Rheumatology · doi:10.1093/mr/road029 · Cited by 3
An update on dıagnosıs and treatment of ANCA assocıated renal vasculıtıs
Türkmen, K., Özer, H., & Tesař, V. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03565-6 · Cited by 3
“Both regimens were equally effective, and less leukopenia developed in the AZA group than in the CYC group [23, 44].”
BackgroundAdvances in the maintenance of ANCA vasculitis remission
Guillevin, L. (2023) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2023.101842 · Cited by 3
Evolution of Therapy for ANCA-Associated Vasculitis with Kidney Involvement
Rajasekaran, A., & Rizk, D. V. (2023) · Kidney360 · doi:10.34067/kid.0000000000000289 · Cited by 5
An update on risk factors for relapse in antineutrophil cytoplasmic antibody-associated vasculitis
Zhou, H., Liang, W., Hu, H., Liu, Z., Chu, F., & Ding, G. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae068 · Cited by 3
Vasculitis asociadas a anticuerpos anticitoplasma de neutr?filo
Alonso, E. R., & Marqus, A. O. (2005) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(05)73594-3 · Cited by 3
Watanabe, H., Sada, K., Matsumoto, Y., Harigai, M., Amano, K., Fujimoto, S., Dobashi, H., Yuzawa, Y., Yamagata, K., Muso, E., et al. (2019) · Modern Rheumatology · doi:10.1080/14397595.2019.1707997 · Cited by 3
Nephrotic syndrome in adults: symptoms and management
(2021) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2021.1.43065 · Cited by 5
Meng, T., Zhu, P., Shen, C., Ooi, J. D., Eggenhuizen, P. J., Zhou, Y.-O., Luo, H., Chen, J.-B., Lin, W., Xiong, Q., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01115-z · Cited by 3
“However, renal insufficiency remains a major challenge for clinicians, which can lead to end stage renal disease (ESRD) and even premature death [6].”
BackgroundThe Molecular Biology and Treatment of Systemic Vasculitis in Children
Eleftheriou, D., & Brogan, P. A. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-906-8_2 · Cited by 3
“This is followed by low-dose corticosteroids and azathioprine (1.5-3 mg/kg/day) to maintain remission [ 3, 178 ] .”
BackgroundInfluentialMoosig, F., Holle, J. U., & Wl, G. (2009) · Der Internist · doi:10.1007/s00108-008-2251-4 · Cited by 3
Horai, Y., Miyamura, T., Takahama, S., Hirata, A., Nakamura, M., Ando, H., Minami, R., Yamamoto, M., & Suematsu, E. (2010) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.33.105 · Cited by 3
de Barros, J. M., Antunes, T., & Barbas, C. S. V. (2005) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132005000700008 · Cited by 4
ANCA-Associated Small Vessel Vasculitis: Clinical and Therapeutic Advances
Mohan, N., & Kerr, G. S. (2010) · Current Rheumatology Reports · doi:10.1007/s11926-010-0137-7 · Cited by 3
“6 compared with those who were ANCA negative [34].”
Inducing remission in ANCA-positive vasculitis: time to RAVE?
Watts, R. A. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.19 · Cited by 3
Metadata
- Authors
- Jayne, D., Rasmussen, N., Andrassy, K., Bacon, P., Tervaert, J. W. C., Dadoniené, J., Ekstrand, A., Gaskin, G., Gregorini, G., de Groot, K., Gross, W., Hagen, E. C., Mirapeix, E., Pettersson, E., Siegert, C., Sinico, A., Tesar, V., Westman, K., & Pusey, C.
- Affiliations
- Addenbrooke's Hospital (GB)
- Rigshospitalet (DK)
- University of Birmingham (GB)
- Maastricht University (NL)
- University of Helsinki (FI)
- Imperial College London (GB)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- University of Lübeck (DE)
- Hospital Clínic de Barcelona (ES)
- Leiden University Medical Center (NL)
- Azienda Ospedaliera Ospedale San Carlo Borromeo (IT)
- Lund University (SE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-07-03
- Volume
- 349
- Issue
- 1
- Pages
- 36-44
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1981535363
- Cited by
- 1,348
- References
- 44
- Citations by year
- 2026: 6 · 2025: 22 · 2024: 24 · 2023: 37 · 2022: 48 · 2021: 36 · 2020: 51 · 2019: 46 · 2018: 51 · 2017: 46 · 2016: 51 · 2015: 80 · 2014: 77 · 2013: 80 · 2012: 83
- FWCI
- 48.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Keywords
- ANCA-associated vasculitis, maintenance therapy, cyclophosphamide, azathioprine, granulomatosis with polyangiitis, microscopic polyangiitis, relapse, remission, prednisolone, adverse events
- MeSH terms
- Adult, Aged, Azathioprine, Cyclophosphamide, Drug Therapy, Combination, Female, Glucocorticoids, Humans, Immunosuppressive Agents, Male, Middle Aged, Neutropenia, Prednisolone, Recurrence, Remission Induction, Vasculitis, Antibodies, Antineutrophil Cytoplasmic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.